T2 Biosystems (TTOO) Stock Price, News & Analysis

Company Overview

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $0.12 to $0.12
• 50-Day Range: $0.06 to $0.29
• 52-Week Range: $0.06 to $6.80
• Volume: 74,862 shs
• Average Volume: 643,142 shs
• Market Capitalization: $2.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

TTOO Stock Analysis - Frequently Asked Questions

How have TTOO shares performed this year?

T2 Biosystems' stock was trading at $0.42 at the beginning of 2025. Since then, TTOO shares have decreased by 71.4% and is now trading at $0.12.
View the best growth stocks for 2025 here.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) posted its quarterly earnings data on Monday, July, 29th. The medical equipment provider reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.31. The medical equipment provider had revenue of $1.95 million for the quarter.

When did T2 Biosystems' stock split?

T2 Biosystems's stock reverse split before market open on Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are T2 Biosystems' major shareholders?

T2 Biosystems' top institutional shareholders include Concourse Financial Group Securities Inc.. Insiders that own company stock include Group LP Cr, John J Sperzel III, Alec Barclay, John M Sprague, Michael Terrence Gibbs, David B Elsbree and Brett A Giffin.
View institutional ownership trends.

How do I buy shares of T2 Biosystems?

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that T2 Biosystems investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Digital Turbine (APPS) and Tesla (TSLA).

Company Calendar

• Last Earnings: 7/29/2024
• Today: 3/25/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TTOO
• CIK: 1492674
• Web: www.t2biosystems.com
• Phone: (781) 761-4646
• Fax: 781-357-3080
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +4,066.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-50,080,000.00
• Net Margins: -563.16%
• Pretax Margin: -559.52%
• Return on Equity: N/A
• Return on Assets: -174.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.40
• Quick Ratio: 0.24

Sales & Book Value

• Annual Sales: $7.68 million
• Price / Sales: 0.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.91) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 21,043,000
• Free Float: 21,037,000
• Market Cap: $2.53 million
• Optionable: Optionable
• Beta: 0.34